The University of Virginia Gene Targeting and Transgenic Facility (GTTF) is a Shared Resource that utilizes advanced transgenic and gene targeting technologies to efficiently produce and preserve genetically engineered mice for cancer model research for UVA Cancer Center investigators. The GTTF's mission is to support transgenic and gene targeting research endeavors, to provide efficient genetic technologies for germline and embryonic stem cell manipulations, and to serve as a resource for design, development and derivation of customized cancer-prone mouse strains. For the past five years, the GTTF has evolved into a unique shared resource that provides a range of integrated services covering five areas: (1) transgenic and knockout/knock-in mouse production, (2) gene targeting, (3) embryo cryopreservation/reconstitution, (4) mouse genetic analysis and (5) training. The GTTF is uniquely positioned to support cancer research. While cancer researchers have successfully studied the molecular and cellular properties of cancer cells propagated in culture, increasingly mouse models of cancer provide a more physiologically relevant opportunity to investigate the interplay of cancer cells, the tumor microenvironment, and the host immune system. Mouse models provide opportunities to study the evolution of cancer progression from first mutations to metastasis, and the unique opportunity to assess the genetic and epigenetic events correlated with acquisition of drug resistance. The overall goal of the GTTF is to provide the support with integrated service and training to make mouse model design, creation and preservation as seamless as possible for the benefit of researchers in the Cancer Center.
Mouse models of cancer provide an essential link between the laboratory and the clinic. The GTTF assists UVA Cancer Center investigators utilize the most sophisticated tools for generating and studying mouse models of human cancer.
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm : |
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437 |
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655 |
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442 |
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9 |
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425 |
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813 |
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815 |
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429 |
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997 |
Showing the most recent 10 out of 539 publications